free web stats

Cytomegalovirus (“CMV”)

VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review

By | Cytomegalovirus ("CMV"), Press Releases
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today announced that, following a review of safety data from the limited safety immunization period, the Data Safety Monitoring Board (“DSMB”) has no objection to VBI continuing with the enrollment of participants...
Read More